Dr. med. Thomas Ruhstaller
Bevacizumab-associated osteonecrosis of the jaw
Greuter S, Schmid F, Ruhstaller T, Thürlimann B. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol 2008; 19:2091-2.
Dec 1, 2008Bevacizumab-associated osteonecrosis of the jaw
Dec 1, 2008Ann Oncol 2008; 19:2091-2
Greuter S, Schmid F, Ruhstaller Thomas, Thürlimann Beat
Fatal herpes simplex virus hepatitis in a patient with esophageal cancer under radiochemotherapy
Grimm B, Padberg B, Ruhstaller T, Fleisch F, von Moos R. Fatal herpes simplex virus hepatitis in a patient with esophageal cancer under radiochemotherapy. Onkologie 2008; 31:620-2.
Nov 1, 2008Fatal herpes simplex virus hepatitis in a patient with esophageal cancer under radiochemotherapy
Nov 1, 2008Onkologie 2008; 31:620-2
Grimm Birgit, Padberg Barbara, Ruhstaller Thomas, Fleisch Felix, von Moos Roger
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research
Koeberle D, Herrmann R, Mora O, Ruhstaller T, Strasser F, Beretta K, Mingrone W, Caspar C, Dietrich D, Gerber D, Borner M, Saletti P, Swiss Group for Clinical Cancer Research. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:3702-8.
Aug 1, 2008Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research
Aug 1, 2008Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:3702-8
Koeberle Dieter, Herrmann Richard, Mora Oreste, Ruhstaller Thomas, Strasser Florian, Beretta Kurt, Mingrone Walter, Caspar Clemens B, Dietrich Daniel, Gerber Daniela, Borner Markus, Saletti Piercarlo, Swiss Group for Clinical Cancer Research
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001
Bernhard J, Pestalozzi B, Köhne C, Mingrone W, Stemmer S, Tàmas K, Kornek G, Koeberle D, Herrmann R, Figer A, Bauer J, Saletti P, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Central European Cooperative Oncology Group. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:3695-701.
Aug 1, 2008Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001
Aug 1, 2008Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:3695-701
Bernhard Jürg, Pestalozzi Bernhard C, Köhne Claus-Henning, Mingrone Walter, Stemmer Salomon M, Tàmas Karin, Kornek Gabriela V, Koeberle Dieter, Herrmann Richard, Figer Arie, Bauer Jean, Saletti Piercarlo, Dietrich Daniel, Scheithauer Werner, Gerber Daniela, Bodoky György, Ruhstaller Thomas, Glimelius Bengt, Bajetta Emilio, Schüller Johannes, Central European Cooperative Oncology Group
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
Borner M, Mingrone W, Lanz D, Dietrich D, Kappeler A, Roth A, Ruhstaller T, Caspar C, Pestalozzi B, Helbling D, Trojan A, Hess V, Rauch D, Saletti P, von Moos R, Koeberle D, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008; 19:1288-92.
Jul 1, 2008Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
Jul 1, 2008Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008; 19:1288-92
Borner M, Mingrone W, Lanz D, Dietrich D, Kappeler A, Roth A, Ruhstaller Thomas, Caspar C, Pestalozzi B, Helbling D, Trojan A, Hess V, Rauch D, Saletti P, von Moos R, Koeberle D, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer
Köberle D, Rust C, Bieri G, Neuweiler J, Terraciano L, Ruhstaller T, Heitzmann F, Hess V, Winterhalder R, von Moos R, Burkhard R, Toepfer M. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. British journal of cancer 2008; 98:1204-9.
Apr 8, 2008Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer
Apr 8, 2008British journal of cancer 2008; 98:1204-9
Köberle Dieter, Rust C, Bieri G, Neuweiler Jörg, Terraciano L, Ruhstaller Thomas, Heitzmann F, Hess V, Winterhalder R, von Moos R, Burkhard R, Toepfer M
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
Hess V, Scheithauer W, Figer A, Saletti P, Bajetta E, Ruhstaller T, Bodoky G, Dietrich D, Grawe P, Glimelius B, Herrmann R. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. The lancet oncology 2008; 9:132-8.
Feb 1, 2008CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
Feb 1, 2008The lancet oncology 2008; 9:132-8
Hess Viviane, Scheithauer Werner, Figer Arie, Saletti Piercarlo, Bajetta Emilio, Ruhstaller Thomas, Bodoky György, Dietrich Daniel, Grawe Philipp, Glimelius Bengt, Herrmann Richard
Adjuvante Chemotherapie: Die Indikation zur Behandlung im Wandel
Ruhstaller T. Adjuvante Chemotherapie: Die Indikation zur Behandlung im Wandel. Hausarztpraxis 2008; 13:14-15.
Jan 1, 2008Adjuvante Chemotherapie: Die Indikation zur Behandlung im Wandel
Jan 1, 2008Hausarztpraxis 2008; 13:14-15
Ruhstaller Thomas
Endocrine symptom assessment in women with breast cancer: what a simple "yes" means
Ribi K, Bernhard J, Rufibach K, Thürlimann B, von Moos R, Ruhstaller T, Glaus A, Böhme C. Endocrine symptom assessment in women with breast cancer: what a simple "yes" means. JSCC 2007; 15:1349-56.
Dec 1, 2007Endocrine symptom assessment in women with breast cancer: what a simple "yes" means
Dec 1, 2007JSCC 2007; 15:1349-56
Ribi K, Bernhard J, Rufibach K, Thürlimann Beat, von Moos R, Ruhstaller Thomas, Glaus A, Böhme C
Is surgery still part of local therapy in patients with locally advanced esophageal carcinoma?
Ruhstaller T, Thürlimann B, Köberle D, von Moos R. Is surgery still part of local therapy in patients with locally advanced esophageal carcinoma?. JCO 2007; 25:4025-6; author reply 4026-7.
Sep 1, 2007Is surgery still part of local therapy in patients with locally advanced esophageal carcinoma?
Sep 1, 2007JCO 2007; 25:4025-6; author reply 4026-7
Ruhstaller Thomas, Thürlimann Beat, Köberle Dieter, von Moos Roger
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Herrmann R, Stemmer S, Tàmas K, Kornek G, Köberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W, Swiss Group for Clinical Cancer Research, Mingrone W, Köhne C, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Central European Cooperative Oncology Group. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:2212-7.
Jun 1, 2007Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Jun 1, 2007Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:2212-7
Herrmann Richard, Stemmer Salomon M, Tàmas Karin, Kornek Gabriela V, Köberle Dieter, Cina Susanne, Bernhard Jürg, Dietrich Daniel, Scheithauer Werner, Swiss Group for Clinical Cancer Research, Mingrone Walter, Köhne Claus-Henning, Bodoky György, Ruhstaller Thomas, Glimelius Bengt, Bajetta Emilio, Schüller Johannes, Saletti Piercarlo, Bauer Jean, Figer Arie, Pestalozzi Bernhard, Central European Cooperative Oncology Group
Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study
Salzberg M, Thürlimann B, Hasler U, Delmore G, von Rohr A, Thurlimann A, Ruhstaller T, Stopatschinskaja S, von Moos R. Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study. Oncology 2007; 72:147-51.
Jan 1, 2007Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study
Jan 1, 2007Oncology 2007; 72:147-51
Salzberg Marc, Thürlimann Beat, Hasler Ursula, Delmore Geoffrey, von Rohr Albert, Thurlimann Annatina, Ruhstaller Thomas, Stopatschinskaja Shanna, von Moos Roger
Das Ösophagus-Karzinom: Eine Krankheit mit vielen Variablen
Ruhstaller T. Das Ösophagus-Karzinom: Eine Krankheit mit vielen Variablen. Leading Opinions 2007; 5:8-11.
Jan 1, 2007Das Ösophagus-Karzinom: Eine Krankheit mit vielen Variablen
Jan 1, 2007Leading Opinions 2007; 5:8-11
Ruhstaller Thomas
The multidisciplinary meeting: An indispensable aid to communication between different specialities
Ruhstaller T, Roe H, Thürlimann B, Nicoll J. The multidisciplinary meeting: An indispensable aid to communication between different specialities. EJC 2006; 42:2459-62.
Oct 1, 2006The multidisciplinary meeting: An indispensable aid to communication between different specialities
Oct 1, 2006EJC 2006; 42:2459-62
Ruhstaller Thomas, Roe Helen, Thürlimann Beat, Nicoll Jonathan J
Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group
Cannabis-In-Cachexia-Study-Group, Reif M, Schnelle M, Ko Y, Meissner W, Ruhstaller T, Ernst G, Possinger K, Luftner D, Strasser F, Cerny T. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24:3394-400.
Jul 20, 2006Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group
Jul 20, 2006Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24:3394-400
Cannabis-In-Cachexia-Study-Group, Reif Marcus, Schnelle Martin, Ko You-Dschun, Meissner Winfried, Ruhstaller Thomas, Ernst Gernot, Possinger Kurt, Luftner Diana, Strasser Florian, Cerny Thomas
Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment
Glaus A, Böhme C, Thürlimann B, Ruhstaller T, Hsu Schmitz S, Morant R, Senn H, von Moos R. Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol 2006; 17:801-6.
May 1, 2006Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment
May 1, 2006Ann Oncol 2006; 17:801-6
Glaus A, Böhme Christel, Thürlimann Beat, Ruhstaller Thomas, Hsu Schmitz S F, Morant R, Senn H J, von Moos R
CASE 3. Red eye in Sjogren's syndrome due to underlying mucosa-associated lymphoid tissue lymphoma
von Moos R, Ruhstaller T, Fretz C. CASE 3. Red eye in Sjogren's syndrome due to underlying mucosa-associated lymphoid tissue lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24:1011-3.
Feb 20, 2006CASE 3. Red eye in Sjogren's syndrome due to underlying mucosa-associated lymphoid tissue lymphoma
Feb 20, 2006Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006; 24:1011-3
von Moos Roger, Ruhstaller Thomas, Fretz Christian
Das Ösophaguskarzinom
Ruhstaller T, Hess V. Das Ösophaguskarzinom. Schweizer Zeitschrift für Onkologie 2006; 3:6-12.
Jan 1, 2006Das Ösophaguskarzinom
Jan 1, 2006Schweizer Zeitschrift für Onkologie 2006; 3:6-12
Ruhstaller Thomas, Hess V
Is there really enough evidence to abandon surgery after radiation chemotherapy in esophageal cancer?
Ruhstaller T, Mueller A, Koeberle D, Thuerlimann B. Is there really enough evidence to abandon surgery after radiation chemotherapy in esophageal cancer?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:8547-8.
Nov 20, 2005Is there really enough evidence to abandon surgery after radiation chemotherapy in esophageal cancer?
Nov 20, 2005Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:8547-8
Ruhstaller Thomas, Mueller Andreas, Koeberle Dieter, Thuerlimann Beat
Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study
Seium Y, Morant R, Bauer J, Trembleau C, Allal A, Philippe M, Mentha G, Gervaz P, Ruhstaller T, Stupp R, Roth A. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:762-6.
May 1, 2005Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study
May 1, 2005Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:762-6
Seium Y, Morant R, Bauer J, Trembleau C, Allal A, Philippe M, Mentha G, Gervaz P, Ruhstaller Thomas, Stupp R, Roth A D